Analysis of accessibility and utilization of national negotiation inhaled drugs for chronic airway diseases in China from 2019 to 2022
OBJECTIVE To grasp the current status of accessibility and clinical use of national negotiation inhalants for chronic airway diseases in China and provide data support for evaluating the implementation effect of national negotiation policy.METHODS Descriptive statistical analysis was utilized for analyzing availability,defined daily doses(DDDs)and defined daily dose cost(DDDc)of national negotiation inhalants for chronic airway diseases in China from 2019 to 2022.The research institu-tions involved 895 secondary and tertiary public general hospitals from 31 provincial administrative regions in China.RESULTS T he availability rate of each investigational drug spiked markedly within the first year of entering the agreement period.And the availability rate of all investigational drugs demonstrated an overall rising trend from 2019 to 2022.As of 2021,the doses of budesonide glycopyrronium bromide and formoterol fumarate inhalation aerosol ranked the first and further rose in 2022,far exceeding other drugs.DDDc of each drug decreased significantly in the first year of agreement period with a declining rate of 61.66％-74.02％.CONCLUSION After the implementation of national medical insurance negotiation policy,availability rate and drug dosage of inhalants for chronic airway diseases have spiked markedly with a substantial decline of DDDc and a greater accessibility of investigated drugs.
national medical insurance negotiationchronic airway diseaseaccessibilitydefined daily dosesdefined daily dose cost
NETL
NSTL
万方数据
